this is why i chose to stay in bhrt, and anncouncement of sales in place would be a great thing.
Bioheart, Inc. (OTCBB:BHRT) and Airspeed Equity LLC, a private investment, entrepreneurial capital management firm, today announced four major products - MyoStim Lab Culture Stimulator, Limb Blood Flow Stimulator, and Implantable Heart Pacemaker and the Biopace Biological Pacemaker.
Airspeed Equity has an exclusive licensing agreement for these products with Bioheart. Under the terms of the Agreement Bioheart will receive milestone based cash payments as well as royalty payments on all net sales. Sales are expected to commence this coming year for the MyoStim Lab Cell Culture Stimulator and MyoStim Limb Blood Flow Stimulator.
"We're excited about developing these four important and potentially life-saving products here in San Diego, the heart of the biotechnology and healthcare community," said Alan Remen, Founder and Managing Director of Airspeed Equity. "This project fits perfectly within our charter to help entrepreneurs, business owners, and major shareholders of companies design strategies for growth and innovation in new and emerging markets."
"The discovery that low voltage electrical stimulation of the heart can both regenerate damaged heart tissue and replace high voltage implantable defibrillators for arrhythmia fibrillation recovery may change the course of care for the more than 30 million patients suffering of heart failure worldwide," said Howard Leonhardt, Bioheart's co-founder and Chief Technology Officer.
News 
Market Data 
Discover 
